VIALE, GIUSEPPE
VIALE, GIUSEPPE
Dipartimento di Oncologia ed Emato-Oncologia
Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer
2025 G. Cursano, A. Concardi, M. Ivanova, C. Frascarelli, E. Mane, E. Mangione, S. Santaguida, D. Tosoni, S. Pece, A. Marra, C. Criscitiello, G. Curigliano, G. Viale, K. Venetis, E.G. Rocco, N. Fusco
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy
2025 K. Venetis, G. Cursano, R. Scafetta, P.P.M.B. Giachetti, A. Concardi, E. De Camilli, M. D'Ercole, E. Mane, C. Frascarelli, A. Marra, S. Gandini, F. Pepe, S. Scagnoli, S.M. Rossi, R. Troiano, E. Speziale, C. De Angelis, G. Troncone, U. Malapelle, G. Perrone, A. Botticelli, G. Viale, G. Curigliano, E. Guerini Rocco, C. Criscitiello, N. Fusco
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis
2024 L. Pala, E. Pagan, I. Sala, C. Oriecuia, M. Oliari, T. De Pas, C. Specchia, E. Cocorocchio, E. Zattarin, G. Rossi, C. Catania, G.L. Ceresoli, D. Laszlo, J. Canzian, E. Valenzi, G. Viale, R.D. Gelber, A. Mantovani, V. Bagnardi, F. Conforti
Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ
2024 E. Guerini-Rocco, F. Bellerba, A. Concardi, S.V. Taormina, G. Cammarata, C. Fumagalli, A. Guerrieri-Gonzaga, D. Macis, E. Del Fiol Manna, E. Balladore, M. Cannone, P. Veronesi, N. Fusco, B. Bonanni, G. Viale, M. Barberis, S. Gandini, M. Lazzeroni
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research
2024 F. Conforti, L. Pala, T. De Pas, E. Zattarin, C. Catania, E. Cocorocchio, G. Rossi, D. Laszlo, M. Colleoni, A. Zambelli, G.N. Hortobagyi, J. Cortes, M.J. Piccart, M. Dowsett, R.D. Gelber, G. Viale
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
2024 M. Ivanova, F.M. Porta, M. D'Ercole, C. Pescia, E. Sajjadi, G. Cursano, E. De Camilli, O. Pala, G. Mazzarol, K. Venetis, E. Guerini-Rocco, G. Curigliano, G. Viale, N. Fusco
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial
2023 D. Serrano, S. Gandini, P. Thomas, K.D. Crew, N.B. Kumar, L.A. Vornik, J.J. Lee, P. Veronesi, G. Viale, A. Guerrieri-Gonzaga, M. Lazzeroni, H. Johansson, M. D'Amico, F. Guasone, S. Spinaci, B. Bertelsen, G. Mellgren, I. Bedrosian, D. Weber, T. Castile, E. Dimond, B.M. Heckman-Stoddard, E. Szabo, P.H. Brown, A. Decensi, B. Bonanni
The molecular landscape of breast mucoepidermoid carcinoma
2023 K. Venetis, E. Sajjadi, M. Ivanova, S. Andaloro, S. Pessina, C. Zanetti, A. Ranghiero, G. Citelli, C. Rossi, M. Lucioni, U. Malapelle, F. Pagni, M. Barberis, E. Guerini-Rocco, G. Viale, N. Fusco
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
2023 L. Ferrando, A. Vingiani, A. Garuti, C. Vernieri, A. Belfiore, L. Agnelli, G. Dagrada, D. Ivanoiu, G. Bonizzi, E. Munzone, L. Lippolis, M. Dameri, F. Ravera, M. Colleoni, G. Viale, L. Magnani, A. Ballestrero, G. Zoppoli, G. Pruneri
Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis
2023 E. Sajjadi, K. Venetis, M. Ivanova, M. Noale, C. Blundo, E. Di Loreto, G. Scarfone, S. Ferrero, S. Maggi, P. Veronesi, V.E. Galimberti, G. Viale, F.A. Peccatori, N. Fusco, E. Guerini-Rocco
Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies
2023 C. Pescia, E. Guerini-Rocco, G. Viale, N. Fusco
TMEM123 a key player in immune surveillance of colorectal cancer
2023 E. Pesce, C. Cordiglieri, M. Bombaci, S. Eppenberger-Castori, S. Oliveto, C. Manara, M. Crosti, C. Ercan, M. Coto, A. Gobbini, S. Campagnoli, T. Donnarumma, M. Martinelli, V. Bevilacqua, E. De Camilli, P. Gruarin, M.L. Sarnicola, E. Cassinotti, L. Baldari, G. Viale, S. Biffo, S. Abrignani, L.M. Terracciano, R. Grifantini
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread
2023 C. Criscitiello, C. Corti, M. De Laurentiis, G. Bianchini, B. Pistilli, S. Cinieri, L. Castellan, G. Arpino, P. Conte, F. DI MECO, A. Gennari, V. Guarneri, L. Visani, L. Livi, P. Marchetti, F. Puglisi, G. Viale, L. Del Mastro, S. De Placido, G. Curigliano
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
2022 K. Venetis, E. Crimini, E. Sajjadi, C. Corti, E. Guerini-Rocco, G. Viale, G. Curigliano, C. Criscitiello, N. Fusco
Sex and cancer immunotherapy: Current understanding and challenges
2022 L. Pala, T. De Pas, C. Catania, G. Giaccone, A. Mantovani, S. Minucci, G. Viale, R.D. Gelber, F. Conforti
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients
2022 E. Montagna, E. Pagan, G. Cancello, C. Sangalli, V. Bagnardi, E. Munzone, E.O. Salè, D. Malengo, M.E. Cazzaniga, M. Negri, G. Peruzzotti, P. Veronesi, G. Viale, M. Colleoni
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
2022 L. Gianni, C.S. Huang, D. Egle, B. Bermejo, C. Zamagni, M. Thill, A. Anton, S. Zambelli, G. Bianchini, S. Russo, E.M. Ciruelos, R. Greil, V. Semiglazov, M. Colleoni, C. Kelly, G. Mariani, L. Del Mastro, I. Maffeis, P. Valagussa, G. Viale
Low-risk triple-negative breast cancers: Clinico-pathological and molecular features
2022 N. Fusco, E. Sajjadi, K. Venetis, M. Ivanova, S. Andaloro, E. Guerini-Rocco, E. Montagna, P. Caldarella, P. Veronesi, M. Colleoni, G. Viale
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study
2022 B. Acs, S.C.Y. Leung, K.M. Kidwell, I. Arun, R. Augulis, S.S. Badve, Y. Bai, A.L. Bane, J.M.S. Bartlett, J. Bayani, G. Bigras, A. Blank, H. Buikema, M.C. Chang, R.L. Dietz, A. Dodson, S. Fineberg, C.M. Focke, D. Gao, A.M. Gown, C. Gutierrez, J. Hartman, Z. Kos, A.-. Laenkholm, A. Laurinavicius, R.M. Levenson, R. Mahboubi-Ardakani, M.G. Mastropasqua, S. Nofech-Mozes, C.K. Osborne, F.M. Penault-Llorca, T. Piper, M.A. Quintayo, T.T. Rau, S. Reinhard, S. Robertson, R. Salgado, T. Sugie, B. van der Vegt, G. Viale, L.A. Zabaglo, D.F. Hayes, M. Dowsett, T.O. Nielsen, D.L. Rimm
Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement
2022 E. Guerini-Rocco, G. Botti, M.P. Foschini, C. Marchio, M.G. Mastropasqua, G. Perrone, E. Roz, A. Santinelli, I. Sassi, V. Galimberti, L. Gianni, G. Viale